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Abstract
Aims Episodes of acute heart failure (AHF) may lead to end-organ dysfunction. In this post hoc analysis of the Relaxin in
Acute Heart Failure trial, we used the MELD-XI (Model of End-Stage Liver Dysfunction) score to examine hepatorenal dysfunc-
tion in patients with AHF.
Methods and results On admission, the MELD-XI score was elevated (abnormal) in 918 (82%) patients, with 638 (57%) hav-
ing isolated renal dysfunction (creatinine > 1 mg/dL), 73 (6.5%) isolated liver dysfunction (bilirubin > 1 mg/dL), and 207
(18.5%) coexisting dysfunction of the kidneys and the liver (both creatinine and bilirubin > 1 mg/dL). The percentage of pa-
tients with elevated MELD-XI score remained constant through a 60 day follow-up, as we observed a gradual decrease of liver
dysfunction prevalence, counterbalanced by an increase in renal dysfunction. Serelaxin treatment was associated with a lower
MELD-XI score on Day 2 and Day 5 (both P < 0.05), but this difference vs. placebo disappeared during longer follow-up. In the
multivariable model, an elevated MELD-XI score on admission was associated with higher 180 day mortality: hazard ratios
(95% confidence interval) for cardiovascular death were 3.10 (1.22–7.87), and for all-cause death 2.47 (1.19–5.15); both
P < 0.05. The addition of the MELD-XI score to a prespecified prognostic model increased the discrimination of the model
for all-cause death, but the increment in the C-index was only modest: 0.013 (P = 0.02).
Conclusions In patients with AHF, hepatorenal dysfunction is prevalent and related to poor outcome. The MELD-XI score is a
useful prognosticator in AHF.
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Introduction
In the recent years, our understanding of the pathophysiology
of acute heart failure (AHF) has evolved, but still, the key un-
derlying mechanisms that can be efficiently targeted have
not been identified.1–3 It has been documented that each ep-
isode of acute decompensation may lead to dysfunction or
injury of end-organs other than the heart, such as the kidneys,
liver, brain, or lungs, with subsequent detrimental conse-
quences.4–11 Typically, though, interest has been focused on
the assessment of each of these organs in isolation while eval-
uating patients with AHF, which is somehow surprising, as the
dysfunction of several organs typically coexists in clinical prac-
tice. Further to this end, the cross-talk between the two
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organs (the liver and the kidneys) whose function has a funda-
mental impact on the natural course of an episode of AHF (the
liver and the kidneys)12–15 has not been thoroughly investi-
gated in this clinical syndrome.
Hepatorenal interaction can be assessed using the MELD
(Model of End-Stage Liver Dysfunction) score that describes
the function of these two organs. The score is calculated on
the basis of creatinine and bilirubin values and was originally
developed to assess the prognosis of patients with advanced
liver disease.16 Recently, it has been implemented in popula-
tions with heart disease including AHF.17–21
Serelaxin is a recombinant form of human relaxin-2, a pep-
tide hormone that mediates cardiovascular and renal adapta-
tions to pregnancy. In the recent RELAX-AHF (Relaxin in Acute
Heart Failure) trial, early administration of serelaxin in pa-
tients with AHF was associated with fewer signs of organ
damage.22 This study is a post hoc analysis of patients en-
rolled into the RELAX-AHF trial in order to evaluate the prev-
alence and prognostic importance of hepatorenal dysfunction
on the basis of the calculation of the MELD score. We also
aimed to assess the impact of serelaxin on hepatorenal
interaction.
Methods
Inclusion/exclusion criteria and study design
The RELAX-AHF was an international, double-blind, placebo-
controlled trial that enrolled 1161 patients admitted to hos-
pital for AHF who were randomly assigned within the first
16 h from presentation to receive 48 h intravenous infu-
sions of either placebo (n = 580) or serelaxin 30 μg/kg
per day (n = 581) on top of standard care. Detailed descrip-
tions of the background and study design as well as the re-
sults of the main study have been published elsewhere.22,23
For entry, patients were required to have dyspnoea, con-
gestion confirmed on chest radiograph, increased brain na-
triuretic peptide (BNP ≥ 350 pg/mL) or N-terminal
prohormone of BNP (NT-proBNP ≥ 1400 pg/mL), mild-to-
moderate renal insufficiency [estimated glomerular filtration
rate (eGFR) between 25 and 75 mL/min/1.73 m2], and sys-
tolic blood pressure > 125 mmHg.
Further exclusion criteria relevant to the analyses
were known, including severe renal impairment
(eGFR < 25 mL/min/1.73 m2) and hepatic impairment [total
bilirubin > 3 mg/dL, or increased ammonia levels (if per-
formed), or cirrhosis with evidence of portal hypertension
such as varices]. Other exclusion criteria are outlined in
the design paper.23,24
Clinical assessments of heart failure signs and symptoms
were performed, and blood samples for laboratory assess-
ments were drawn at baseline, 24 h (Day 1), 48 h (Day 2),
Days 3–4 (if patient was still in hospital), and Days 5, 14,
and 60. All laboratory tests were conducted in the central
laboratory.
The RELAX-AHF trial fulfilled the requirements stated in the
Declaration of Helsinki, and the protocol was independently
approved by the ethics committee at each participating cen-
tre; written informed consent was obtained from each
participant.
Model of End-Stage Liver Dysfunction excluding
INR (MELD-XI) calculations
Originally, MELD was developed and validated to assess prog-
nosis in patients with advanced liver disease awaiting liver
transplant or transjugular intrahepatic portosystemic shunt
procedure.12,13 As the original MELD formula uses interna-
tional normalized ratio (INR) values for risk stratification, it
cannot be used in patients on vitamin K antagonists (oral an-
ticoagulants). Thus, in this population, modification of the
score excluding INR (MELD-XI) was developed by Heuman
et al.16 and used for these analyses: [5.11 × loge bilirubin
(mg/dL)] + [11.76 × loge creatinine (mg/dL)] + 9.44. Following
the recommendations of the United Network for Organ Shar-
ing for liver transplant organ allocation in the USA and other
authors, the lower limit of bilirubin and creatinine was set at
1.0 mg/dL (SI units: 17.1 and 88.4 μmol/L, respectively).16
This correction is recommended to prevent negative scores,
as the logarithms of values lower than 1.0 are negative. Thus,
for the analysis, values of bilirubin or creatinine < 1 mg/dL
were assigned a value of 1 mg/dL when computing the
MELD-XI score. As the logarithm of 1.0 equals 0, a
value < 1 mg/dL for either component does not impact the
score. If both components are ≤1 mg/dL, the final score is
9.44 (the lowest possible); consequently, any score above
that cut-off was considered elevated.
For the purpose of this analysis, and to be consistent with
the definition of elevated MELD-XI, the cut-offs for organ dys-
function were defined by values of creatinine and bilirubin of
1 mg/dL; that is, patients with creatinine or bilirubin
values > 1 mg/dL were considered as having isolated kidney
or liver dysfunction, respectively, or concurrent organ dys-
function, if both were elevated. Any MELD-XI score > 9.44
points was considered elevated; thus, the study population
was arbitrary dichotomized with the MELD-XI cut-off.
Endpoints of the present analysis
The primary and secondary endpoints of the RELAX-AHF trial
are presented in previous papers.23,24 The outcomes for this
analysis were all-cause and cardiovascular mortality within
180 days from randomization.
J. Biegus et al.
DOI: 10.1002/ehf2.12477
1189
ESC Heart Failure 2019; 6: 1188–1198
Statistical analyses
Continuous variables are reported as mean ± standard
deviation for normally distributed variables and median (in-
ter-quartile range) for non-normally distributed variables; cat-
egorical variables are reported as percentages. Differences in
baseline characteristics between the subgroups of patients
with a different status of kidney/liver dysfunction at baseline
were tested for by using one-way ANOVA or Kruskal–Wallis
rank test for continuous data and a χ2 test for categorical data.
Individual MELD-XI scores were calculated at baseline and
on Days 2, 5, 14, and 60 using the equation developed by
Heuman et al. From this, the proportion of patients with an
elevated MELD-XI score at each of these time points was
calculated, and the individual contributors of an elevated
MELD-XI score were assessed by calculating the proportion
of patients with isolated liver dysfunction, isolated renal dys-
function, or coexisting dysfunction of kidneys and liver. Next,
the pattern of change in MELD-XI score over time until Day 60
was assessed by fitting a linear mixed effects model to the
longitudinal measurements taken at baseline and on Days 2,
5, 14, and 60. Missingness due to mortality events before
Day 60 was accounted for in the analysis by jointly modelling
the longitudinal process and the survival process. Differences
in the mean trajectories of the MELD-XI score in the serelaxin
and placebo groups were tested for by including interaction
terms with the time components in the mixed effects model.
Similar models were subsequently fitted to describe the aver-
age bilirubin and creatinine trajectories.
The association between the baseline MELD-XI score (both
continuous and dichotomized into elevated/normal) and the
outcomes of interest were assessed using Cox proportional
hazards models. Both unadjusted models and models
adjusted for previously established predictors of those
outcomes (geographic region, systolic blood pressure,
orthopnoea, angina, hyperthyroidism, mitral regurgitation,
atrial fibrillation/flutter at screening, white blood cell count,
lymphocyte %, blood urea nitrogen, sodium, potassium, cal-
cium, total protein, NT-proBNP, high sensitive troponin T
(hs-TnT), and study treatment for 180 day cardiovascular
mortality; age, congestive heart failure within 1 month prior
to randomization, history of stroke/cerebrovascular accident
(CVA), respiratory rate, systolic blood pressure, peripheral oe-
dema, orthopnoea, lymphocyte%, sodium, troponin T, and
study treatment for 180 day all-cause mortality) were fitted.
Next, to assess whether treatment with serelaxin modifies
the effect of the MELD-XI score, interaction terms were
added to both the unadjusted and adjusted models. Finally,
the added predictive value of baseline MELD-XI score, creati-
nine, and bilirubin on top of the predictors included in the ad-
justed Cox models was assessed by calculating the change in
Harrell’s C-index as well as the continuous net reclassification
improvement (cNRI). The cNRI is a category-independent
metric that quantifies the amount of correct change in
model-based predicted probabilities obtained by adding a
biomarker to an established model. C-statistics was used to
compare the goodness of fit of logistic regression models. In
simple words, the higher the C-index, the higher the prognos-
tic accuracy of the model. So the gain in C-index is related to
improvement of the prognostic abilities of the model.
All patients with available MELD-XI score values at baseline
were included in these analyses. Missing values for the other
predictor variables were imputed with study treatment-
specific median values. Similar analyses were additionally
conducted for the individual components of the MELD-XI
score (i.e. creatinine and bilirubin). P-values < 0.05 were con-
sidered to be statistically significant. All analyses were per-
formed with R: A Language and Environment for Statistical
Computing, version 3.0.2 (R Foundation for Statistical Com-
puting, Vienna, Austria).
Results
Prevalence of abnormal MELD-XI and its
contributors at baseline and during follow-up
Among patients enrolled into the RELAX-AHF trial, 1120 had
baseline creatinine and bilirubin data available, of whom
Table 1 Proportion of patients with elevated MELD-XI score and individual contributors (elevated creatinine only, elevated bilirubin only,
and both) at prespecified time points
Time of evaluation
Elevated
MELD-XI score
Isolated renal
dysfunction
Isolated liver
dysfunction
Coexisting hepatorenal
dysfunction
Admission, % (n = 1120) 82.0 (918) 57.0 (638) 6.5 (73) 18.5 (207)
Day 2, % (n = 1092) 79.0 (863) 56.7 (619) 6.4 (70) 15.9 (174)
Day 5, % (n = 1058) 82.3 (871) 66.9 (708) 3.6 (38) 11.8 (125)
Day 14, % (n = 1036) 83.4 (864) 73.4 (760) 1.5 (16) 8.5 (88)
Day 60, % (n = 953) 79.5 (758) 69.0 (658) 2.8 (27) 7.7 (73)
Elevated MELD-XI score: MELD-XI score > 9.44. Isolated renal dysfunction: serum creatinine > 1 mg/dL (>88.4 μmol/L) with serum biliru-
bin ≤ 1 mg/dL (>17.1 μmol/L). Isolated liver dysfunction: serum bilirubin > 1 mg/dL with serum creatinine ≤ 1 mg/dL. Coexisting
hepatorenal dysfunction–serum creatinine > 1 mg/dL and serum bilirubin > 1 mg/dL.
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Table 2 Comparison of baseline characteristics in patients with different patterns of abnormalities contributing to elevated MELD-XI
score
Variable
Normal MELD-XI
score
(n = 202)
Isolated renal
dysfunction
(n = 638)
Isolated liver
dysfunction
(n = 73)
Coexisting
hepatorenal
dysfunction (n = 207) P-value
MELD-XI score 9.44 ± 0 13.68 ± 2.4 11.25 ± 1.3 15.71 ± 2.89 <0.0001
Age (years) 73.83 ± 10.73 72.31 ± 11.15 72.19 ± 8.11 69.77 ± 12.31 0.0027
Sex (male) 26.2 (53) 69.1 (441) 47.9 (35) 80.7 (167) <0.001
Race (White) 98.5 (199) 93.9 (599) 98.6 (72) 92.3 (191) 0.0096
Weight (kg) 76.54 ± 18.69 83.31 ± 18.26 78.45 ± 14.35 85.2 ± 19.07 <0.0001
BMI (kg/m2) 28.52 ± 6.03 29.65 ± 5.72 28.59 ± 5.05 28.93 ± 5.42 0.045
Systolic blood pressure
(mmHg)
142.96 ± 16.32 143.11 ± 16.7 141.27 ± 13.1 139.09 ± 16.64 0.019
Diastolic blood pressure
(mmHg)
78.02 ± 13.47 78.36 ± 14.49 80.14 ± 10.76 81.55 ± 14.89 0.025
Heart rate (b.p.m.) 81.55 ± 14.96 78.61 ± 14.85 82.7 ± 16.6 80.88 ± 14.1 0.014
Respiratory rate
(breaths per minute)
22.34 ± 4.85 21.77 ± 4.52 21.89 ± 4.97 21.83 ± 4.49 0.51
Past HF hospitalization 20.8 (42) 35.3 (225) 30.1 (22) 42.5 (88) <0.0001
Number
of hospitalizations
1.3 ± 0.71 1.63 ± 1.26 1.5 ± 0.86 1.84 ± 1.68 0.17
LVEF, % 42.49 ± 14.13 39.41 ± 14.04 36.6 ± 14.4 33.26 ± 15.17 <0.0001
NYHA class 30 days
before admission
0.098
I 1.6 (2) 3.4 (16) 0 (0) 2.4 (4)
II 39.8 (51) 36.3 (173) 41.2 (21) 27.3 (45)
III 39.8 (51) 43.7 (208) 45.1 (23) 57 (94)
IV 18.8 (24) 16.6 (79) 13.7 (7) 13.3 (22)
Hypertension 86.1 (174) 89.3 (570) 83.6 (61) 78.7 (163) 0.0014
Mitral regurgitation 27.2 (55) 30.4 (194) 32.9 (24) 38.6 (80) 0.071
Ischaemic heart disease 40.1 (81) 57.5 (367) 43.8 (32) 49.8 (103) <0.0001
Implantable cardiac
defibrillator
7.9 (16) 14.4 (92) 2.7 (2) 18.8 (39) 0.00038
Atrial fibrillation 51.5 (104) 47.8 (305) 63 (46) 61.4 (127) 0.0016
Congestive heart failure
1 month prior
64.4 (130) 75.5 (482) 69.9 (51) 80.7 (167) 0.0011
Atrial fibrillation at
screening
39.6 (80) 36.8 (235) 53.4 (39) 51.2 (106) 0.00038
ACE inhibitor 58.9 (119) 55.3 (353) 54.8 (40) 47.8 (99) 0.14
Angiotensin receptor
blocker
14.4 (29) 16.3 (104) 13.7 (10) 18.4 (38) 0.67
Beta-blocker 67.3 (136) 68 (434) 63 (46) 73.9 (153) 0.26
PO loop diuretic 30 days prior 22.3 (45) 33.9 (216) 28.8 (21) 32.9 (68) 0.018
Dyspnoea by VAS, mm 44.34 ± 18.89 44.37 ± 19.87 41.81 ± 19.84 42.99 ± 20.69 0.64
General well-being by
VAS, mm
44.22 ± 18.33 44.63 ± 19.05 42.47 ± 19.76 44.48 ± 20.36 0.84
Dyspnoea on exertion 100 (200) 99.5 (630) 100 (71) 99.5 (201) 0.73
Orthopnoea 95 (192) 96.2 (613) 95.9 (70) 95.7 (198) 0.9
Oedema 71.8 (145) 79.9 (509) 80.8 (59) 81.2 (168) 0.064
Rales 95 (192) 95.6 (610) 94.5 (69) 91.8 (190) 0.2
Jugular venous pressure 69.5 (137) 76.7 (476) 69 (49) 79.2 (160) 0.063
Alanine transaminase,
U/L
23 [16.25–33] 21 [15–31] 22 [16–35] 23 [17–33.25] 0.0073
Albumin, g/L 4 ± 0.42 4.02 ± 0.42 4.08 ± 0.44 4.02 ± 0.49 0.64
Aspartate transaminase, U/L 25 [20–34.25] 23 [19–32] 29 [23–35.75] 27 [23–36] <0.0001
BUN, mmol/L 19.83 ± 7.22 29.9 ± 11.32 18.45 ± 5.23 30.22 ± 11.22 <0.0001
Creatinine, mg/dL 0.89 ± 0.11 1.47 ± 0.33 0.89 ± 0.12 1.43 ± 0.29 <0.0001
Bilirubin, mg/dL 0.55 ± 0.21 0.58 ± 0.21 1.48 ± 0.44 1.67 ± 0.74 <0.0001
Haemoglobin, g/dL 12.8 ± 1.59 12.54 ± 1.84 13.32 ± 1.99 13.29 ± 1.97 <0.0001
WBC, ×10/L 8.43 ± 2.93 8.24 ± 2.76 7.56 ± 2.66 7.83 ± 2.84 0.04
Potassium, mmol/L 4.11 ± 0.57 4.35 ± 0.61 4.01 ± 0.44 4.29 ± 0.75 <0.0001
Sodium, mmol/L 141.3 ± 3.35 140.97 ± 3.29 140.18 ± 4.16 140.23 ± 4.3 0.0054
(Continues)
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918 (82%) had an elevated MELD-XI score. Again, any MELD-
XI score above the minimal possible value (9.44 points) was
considered elevated. The mean baseline MELD-XI score was
13.1 ± 3.01 points with no difference between the serelaxin
and placebo groups. The major contributors to the elevated
baseline score were isolated renal dysfunction in 638 patients
(57%), coexisting dysfunction of kidney and liver in 207
(18.5%), and isolated liver dysfunction in 73 (6.5%) (Table
1). The percentage of patients with an elevated MELD-XI
score remained fairly constant (at the rate of 80%) through
a 60 day follow-up. We observed a gradual decrease of iso-
lated liver dysfunction (from 6.5% at baseline to 2.8% on
Day 60) and hepatorenal dysfunction (from 18.5% at baseline
to 7.7% on Day 60), which was counterbalanced by an in-
crease of the number of patients with isolated renal dysfunc-
tion (an increase from 57% at baseline to 69% on Day 60)
(Table 1).
Characteristics of patients with hepatorenal
dysfunction
Detailed baseline characteristics of the RELAX-AHF study
population have already been presented.23 A comparison
of the baseline characteristics of patients with kidney, liver,
and coexisting kidney and liver dysfunction is presented in
Table 2. Patients with coexisting hepatorenal dysfunction,
when compared with the rest of the population, were
younger, were more likely to be men, and with previous
history of heart failure. They also presented signs of more
advanced heart failure with lower ejection fraction, lower
baseline systolic blood pressure, higher NT-proBNP,
and more often biventricular pacemaker implanted (all
P < 0.05) (Table 2). Interestingly, patients with hepatorenal
dysfunction, when compared with the rest of the group,
did not differ with respect to most clinical signs on
admission.
Trajectories of MELD-XI and its contributors
through Day 60 in the serelaxin and placebo
groups
The average trajectories, estimated from the joint
longitudinal–survival models, showed significant differences
between the serelaxin and placebo groups with respect to
changes in the MELD-XI score (interaction P < 0.001) and
creatinine (interaction P < 0.001), but not bilirubin (interac-
tion P = 0.076), through Day 60. The mean MELD-XI score
and creatinine value decreased in the serelaxin group and
increased in the placebo group during the first 2 days but
were similar in the two groups by Day 14 and through
Day 60 (Figure 1). Patients receiving serelaxin had a signifi-
cantly lower mean MELD-XI score, and consequently, fewer
patients had an elevated score, than had the placebo group
on Day 2 and Day 5 (12.8 ± 3.13 vs. 13.5 ± 3.36 and
13.44.8 ± 3.44 vs. 13.97 ± 3.60, respectively, both
P < 0.05), but this difference was no longer evident in a
60 day follow-up (Table 3, Figure 2).
Prognostic significance of hepatorenal
dysfunction
There were 84 (7.2%) cardiovascular deaths and 102 (8.4%)
all-cause deaths through Day 180. After multivariable adjust-
ment, an elevated baseline MELD-XI score was associated
with higher 180 day cardiovascular as well as all-cause mor-
tality hazard ratio (HR) (95% CI) of 3.1 (1.22–7.87) and HR
(95% CI) of 2.47 (1.19–5.15), respectively, both P < 0.05 (Ta-
ble 4). Analogously, when the score was analysed as a contin-
uous predictor, we found it to be significantly related to both
prespecified outcomes: for CV death, HR (95% CI) of 1.14
(1.08–1.21) and for all-cause death HR (95% CI) of 1.11
(1.04–1.17), respectively (both P < 0.05) (Table 4). Patients
with coexistence of liver and kidney dysfunction had signifi-
cantly worse outcome than had the rest of the population;
Table 2 (continued)
Variable
Normal MELD-XI
score
(n = 202)
Isolated renal
dysfunction
(n = 638)
Isolated liver
dysfunction
(n = 73)
Coexisting
hepatorenal
dysfunction (n = 207) P-value
Total cholesterol, mmol/L 171.11 ± 46.86 159.91 ± 44.75 151.63 ± 47.83 141.14 ± 37.72 <0.0001
Total protein, g/L 6.7 ± 0.65 6.8 ± 0.65 6.84 ± 0.6 6.85 ± 0.63 0.12
Triglycerides, mmol/L 92 [64–125] 98 [73–139.25] 73 [55–86] 82 [61.5–108.5] <0.0001
NT-proBNP, pg/mL 4246
[2508–7814]
4633
[2596.75–9109.75]
4315
[2949–7835]
6345.5
[3466–10 486.75]
0.00018
hs-cTnT, μg/L 0.03 [0.02–0.05] 0.04 [0.02–0.06] 0.03 [0.02–0.03] 0.04 [0.02–0.05] <0.0001
Normal MELD-XI score = 9.44. Isolated renal dysfunction: serum creatinine > 1 mg/dL with serum bilirubin ≤ 1 mg/dL. Isolated liver dys-
function: serum bilirubin > 1 mg/dL with serum creatinine ≤ 1 mg/dL. Coexisting hepatorenal dysfunction: serum creatinine > 1 mg/dL
and serum bilirubin > 1 mg/dL. Data shown are as percentage (number), mean ± SD, median [Q25%–Q75%].
BMI, body mass index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; VAS, visual analogue scale.
DOI: 10.1002/ehf2.12477
1192
ESC Heart Failure 2019; 6: 1188–1198
Prognostic significance of hepatorenal dysfunction in AHF
the HR (95% CI) for cardiovascular death and for all-cause
death was 5.05 (1.85–13.76) and 4.24 (1.91–9.4), respec-
tively, both P < 0.05.
Interaction analysis between study treatment,
baseline MELD-XI, and its contributors
In general, interaction analyses showed no significant
differential effect of study treatment on 180 day mortality
in patients with different organ dysfunction profiles (all
P > 0.05) (Table 5). Only the group without coexistence of
hepatorenal dysfunction had significantly lower risk of mor-
tality when treated with serelaxin than had the rest of the
population (P = 0.046 for interaction).
Additive prognostic importance of hepatorenal
dysfunction in acute heart failure
We tested the prognostic value of organ dysfunction over
that provided by the baseline characteristics in a
prespecified multivariable model.25,26 The addition of either
creatinine or bilirubin to the prespecified model did not re-
sult in a significant gain of the model’s prognostic power
(Table 6). Only the addition of either MELD-XI or
hepatorenal dysfunction to the model increased the
model’s discrimination for all-cause death; however, the
gain in the C-index was only modest: 0.013 and 0.010, re-
spectively (both P < 0.05) (Table 6).25,26
Discussion
There are important messages in this post hoc analysis of the
RELAX-AHF trial. Firstly, we found that a dysfunction of two or-
gans—the liver and kidney—is prevalent in patients with AHF,
as ~80% of the population had an elevated MELD-XI score, sig-
nifying dysfunction of at least one organ, close to the time of
admission, and it remained prevalent until Day 60. This high
prevalence may be partially related to the design of the
RELAX-AHF trial, which included patients with decreased eGFR
(in the range of 25–75 mL/min/1.73 m2), so renal dysfunction
was the main contributor to an elevated MELD-XI score.
Figure 1 Bar graphs representing the proportion of patients with an elevated MELD-XI score and individual contributors (elevated creatinine only, el-
evated bilirubin only, and both) at each of the prespecified time points in placebo vs. serelaxin treatment groups (*P < 0.05, **P < 0.001).
Table 3 Mean (SD) values of MELD-XI score at prespecified time
points in all patients and comparison of the MELD-XI score in
groups stratified by study treatment
Time
point
Mean ± SD values of MELD at prespecified time points
All patients Placebo Serelaxin P-value
Baseline 13.13 ± 3.01 13.11 ± 2.99 13.16 ± 3.03 0.800
Day 2 13.15 ± 3.26 13.5 ± 3.36 12.8 ± 3.13 0.0004
Day 5 13.71 ± 3.53 13.97 ± 3.60 13.44 ± 3.44 0.015
Day 14 13.84 ± 3.56 13.87 ± 3.44 13.81 ± 3.68 0.800
Day 60 13.37 ± 3.39 13.34 ± 3.27 13.39 ± 3.52 0.830
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Importantly, though, we observed coexistence of liver and kid-
ney dysfunction to be commonly present on admission (18.5%
of all patients) with a gradual decrease over time. Still, how-
ever, ~10% of the trial population demonstrated evidence of
liver dysfunction on both Days 14 and 60. Onewould expect in-
tuitively that dysfunction of both organs would be frequent
only in patients with overt signs of hypoperfusion and/or low
blood pressure. Surprisingly, we revealed that end-organ
dysfunction can be prevalent even in AHF patients with
normal/high blood pressure (as ~18.5% of patients had both
liver and kidney affected). Thus, the score could be used in
the whole spectrum of heart failure patients, even without
over clinical signs of multiorgan dysfunction.
Secondly, we found that patients with concurrent
hepatorenal dysfunction had very unfavourable prognosis.
We have demonstrated that any elevation of MELD-XI
Figure 2 Average trajectories (based on the fixed effects of the longitudinal component of the joint model) of MELD-XI score, creatinine, and bilirubin
over time in placebo vs. serelaxin treatment groups; interaction P-value indicates statistical significance of differences in the trajectories of the markers
in the placebo vs. serelaxin treatment groups.
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Prognostic significance of hepatorenal dysfunction in AHF
defined as being above the minimal value (which is 9.44
points) had prognostic significance. Interestingly, the analyses
showed that isolated organ dysfunction, defined by a cut-off
of 1 mg/dL for serum creatinine and bilirubin, has a much
weaker prognostic significance, as only isolated liver dysfunc-
tion was associated with a higher risk of 180 day cardiovascu-
lar death. This may be seen as somehow unexpected,
because renal dysfunction, defined as elevated creatinine, is
a well-established prognosticator in heart failure, in both
chronic and acute settings. In our study, patients who pre-
sented dysfunction of both organs on admission had a much
higher risk of both all-cause and cardiovascular death, than
had particularly those with a normal MELD-XI (four-fold to
five-fold increase). This observation goes with agreement
with recently published data, in which AHF patients present-
ing with higher number of dysfunctional/injured organs on
admission had much worse outcome, than had those with
lower numbers or no signs of dysfunction.27 Analogically to
present analyses, the dysfunction of two organs (kidney, liver,
or heart) was related to 3.5-fold higher 1 year mortality.27 Co-
existence of hepatorenal dysfunction identified patients with
more advanced heart failure (as evidenced by lower ejection
fraction, lower systolic blood pressure, higher NT-proBNP,
higher rate of history of chronic heart failure, and higher
rates of oedema), but the association with poor outcomes
remained highly statistically significant after multivariable ad-
justment. Importantly, there were no obvious clinical signs
identifying patients with hepatorenal dysfunction on admis-
sion. This group of patients may be more prone to organ
injury or experience more profound haemodynamic, meta-
bolic, or neurohormonal disturbances leading to multiorgan
dysfunction that cannot be detected by simple clinical exam-
ination. There is growing evidence on several vasoactive
molecules such as nitric oxide, endothelin, adenosine, prosta-
glandins, and endotoxins that can affect not only systemic
but also splanchnic circulation and, therefore, promote organ
dysfunction in heart failure settings. Moreover, sympathetic
tone, volume status, and intraabdominal pressure affect or-
gan perfusion pressure, which is crucial for its optimal func-
tion. We believe that organ dysfunction in AHF is most
likely a result of concurrence of several mechanisms, rather
than the effect of one.28,29 We can include among them
Table 4 Prognostic significance of hepatorenal dysfunction (MELD-XI score and its contributors) in RELAX-AHF population
Predictor
Time to cardiovascular death through Day 180 Time to all-cause death through Day 180
Unadjusted Adjusteda Unadjusted Adjustedb
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Elevated MELD-XI score
(yes vs. no)
3.62 (1.47–8.95) 0.005 3.10 (1.22–7.87) 0.017 2.70 (1.31–5.56) 0.007 2.47 (1.19–5.15) 0.015
MELD-XI score,
continuous (points)
1.16 (1.09–1.23) <0.001 1.09 (1.02–1.16) 0.007 1.14 (1.08–1.21) <0.001 1.11 (1.04–1.17) <0.001
Creatinine, continuous
(mg/dL)
4.54 (2.11–9.76) <0.001 2.49 (1.08–5.73) 0.033 4.16 (2.07–8.37) <0.001 2.85 (1.43–5.65) 0.003
Bilirubin,
continuous (mg/dL)
1.68 (1.19–2.36) 0.003 1.71 (1.20–2.46) 0.003 1.53 (1.12–2.09) 0.007 1.58 (1.14–2.20) 0.006
HR should be interpreted per one-unit increment for continuous predictors; creatinine and bilirubin were natural-log transformed.
aAdjusted for geographic region, systolic blood pressure, orthopnoea, angina, hyperthyroidism, mitral regurgitation, atrial fibrillation/flut-
ter at screening, white blood cell count, lymphocyte %, sodium, potassium, calcium, total protein, log2 NT-proBNP, log2 hs-cTnT, and
study treatment.
bAdjusted for age, congestive heart failure within 1 month prior to randomization, history of stroke/CVA, respiratory rate, systolic blood
pressure, peripheral oedema, orthopnoea, lymphocyte %, sodium, log2 hs-cTnT, and study treatment.
Table 5 Effect of serelaxin on time-to-event outcomes in patients with elevated vs. non-elevated baseline MELD-XI score and its compo-
nents—an interaction analysis
Variable
Time to cardiovascular death through Day 180 Time to all-cause death through Day 180
Elevated variablea
Interaction
P-value
Elevated variablea
Interaction
P-value
No Yes No Yes
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
MELD-XI score > 9.44 1.58 (0.26–9.44) 0.59 (0.38–0.93) 0.290 1.75 (0.42–7.40) 0.57 (0.38–0.87) 0.130
Creatinine > 1 mg/dL 0.84 (0.25–2.74) 0.60 (0.38–0.96) 0.620 1.00 (0.35–2.86) 0.58 (0.38–0.89) 0.350
Bilirubin > 1 mg/dL 0.46 (0.26–0.84) 0.98 (0.50–1.91) 0.100 0.53 (0.31–0.88) 0.83 (0.44–0.57) 0.270
Kidney and liver dysfunction 0.46 (0.26–0.81) 1.18 (0.56–2.48) 0.046 0.52 (0.32–0.96) 0.96 (0.49–1.91) 0.150
HR represents the hazard ratios for the effect of serelaxin treatment in subgroups of patients defined based on MELD-XI score, creatinine,
and bilirubin; kidney and liver dysfunction represents both serum creatinine and bilirubin > 1 mg/dL.
aMELD-XI, creatinine, bilirubin, or kidney and liver dysfunction, where appropriate (according to the rows).
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low cardiac output (forward failure; however, it seems to
have marginal role), low organ perfusion (the difference be-
tween mean arterial pressure and central venous pressure),
lactate accumulation, activation of adrenergic drive, tricuspid
valve insufficiency, right ventricle failure (backward failure),
elevated central venous, and intraabdominal pressure.29–35
Among them, congestion and central venous pressure seem
to play a crucial role.36 Indeed, in RELAX, patients with coex-
istence of renal and liver dysfunction had some signs of more
advanced heart failure and congestion (refer to previous
discussion).
The mean MELD-XI score in the RELAX-AHF trial was 13
points. Other authors have reported the mean score in
AHF populations to be between 10 and 15 points.17,21,37
We have demonstrated that the score remained fairly
unchanged during the hospital stay as well as during the
post-discharge phase until Day 60. However, we observed
a gradual decrease in patients with isolated liver dysfunc-
tion and hepatorenal dysfunction, which was counter-
balanced by an increase in the percentage of those who
demonstrated isolated kidney dysfunction. This observation
seems somehow counterintuitive to the traditional view of
organ dysfunction in AHF, as we believe that mechanisms
leading to or underlying decompensation of heart failure
may also lead to functional deterioration of other organs.27
Thus, one would rather expect the number of patients with
organ dysfunction to decrease during the post-discharge
phase.
Metra et al. have already shown an analysis of organ func-
tion during the serelaxin infusion phase of RELAX studies.22
However, we present the problem (of multiorgan dysfunction
in AHF) from a slightly different perspective. Firstly, we have
shown a longer follow-up of the organ function (up to Day
60). This turned out to be a crucial, as the improvement of
creatinine was only limited to the phase of active drug infu-
sion. Secondly, we have provided the data of creatinine, bili-
rubin, and MELD-XI as continuous and categorized variables,
whereas previous paper showed only categorized data.22
Thirdly, we think the MELD-XI score is a unique marker that
may combine the information of both organ (liver and kidney)
dysfunction, while Metra had shown an analyses of each or-
gan in separation. We believe that the interplay between or-
gan dysfunction may identify patients at highest risk of
adverse outcome in heart failure.
Additionally, we analysed the trajectories of creatinine,
bilirubin, and MELD-XI over time and found that the differ-
ences are related to therapy. Patients who received
serelaxin experienced a mean decrease in creatinine, but
no changes in bilirubin, during the first 48 h (i.e. during drug
infusion), which resulted in a decrease in mean MELD-XI
score. After active therapy discontinuation, the trajectories
of creatinine and MELD-XI became similar in the serelaxin
and placebo groups (Figure 2). Interestingly, patients with
both organs affected experienced the most obvious organTa
b
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Prognostic significance of hepatorenal dysfunction in AHF
protective benefits of the treatment. The difference in per-
centage of patients with elevated MELD-XI at Day 2, between
placebo and serelaxin groups, was driven by a decrease of per-
centage of patients with both organs affected, which was
counterbalanced by an increase of patients with elevated
bilirubin alone (Figure 1). These findings confirm the previous
observation that serelaxin demonstrated end-organ protec-
tive effects in AHF, but most likely, it was restricted only to a
period of active drug infusion.22 Moreover, we can only spec-
ulate that impermanent effect of the serelaxin on organ
dysfunction may be one of the reasons that there was no
impact on mortality in the RELAX study.23,25
Lastly, the biological importance of kidney and liver func-
tion is far more complex than can be assessed by measure-
ment of creatinine and bilirubin. Thus, novel and promising
markers of organ dysfunction as a result of heart failure se-
verity have been proposed, like the assessment of liver stiff-
ness (a marker related to congestion and liver remodelling
as a result of congestion), assessment of urine sodium (a
marker of renal water–sodium handling in heart failure), or
serum osmolarity.38–41 In the future, we will probably use a
multimarket approach to assess a single organ as well as in-
terplay between organs.
Study limitations
As this is a post hoc analysis of a population included in a
clinical trial, it may not describe the scale of the problem of
liver and kidney dysfunction in the whole spectrum of un-
selected AHF patients. On the one hand, the inclusion
criteria resulted in an overestimation of the number of pa-
tients with an elevated MELD-XI (due to kidney dysfunc-
tion); on the other hand, the exclusion criteria eliminated
patients with profoundly elevated bilirubin (>3 mg/dL)
and creatinine (with eGFR < 25 mL/min/1.73 m2). The lim-
ited number of deaths in patients with a normal MELD-XI
score (i.e. <9.44 points) of 5 (0.4%) cardiovascular and 8
(0.68%) and all-cause deaths is another important limitation
of the presented data.
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